Eliem Therapeutics, Inc. (ELYM): Price and Financial Metrics


Eliem Therapeutics, Inc. (ELYM): $3.85

0.23 (+6.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ELYM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ELYM Stock Price Chart Interactive Chart >

Price chart for ELYM

ELYM Price/Volume Stats

Current price $3.85 52-week high $11.51
Prev. close $3.62 52-week low $2.36
Day low $3.64 Volume 1,200
Day high $3.85 Avg. volume 18,500
50-day MA $3.17 Dividend yield N/A
200-day MA $3.59 Market Cap 102.29M

Eliem Therapeutics, Inc. (ELYM) Company Bio


Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.


ELYM Latest News Stream


Event/Time News Detail
Loading, please wait...

ELYM Latest Social Stream


Loading social stream, please wait...

View Full ELYM Social Stream

Latest ELYM News From Around the Web

Below are the latest news stories about ELIEM THERAPEUTICS INC that investors may wish to consider to help them evaluate ELYM as an investment opportunity.

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.

GlobeNewswire | November 30, 2022

Eliem Theraputics (NASDAQ:ELYM)

The following slide deck was published by Eliem Therapeutics, Inc.

Seeking Alpha | November 18, 2022

Eliem Therapeutics GAAP EPS of -$0.37 beats by $0.06 (NASDAQ:ELYM)

Eliem Therapeutics press release (ELYM): Q3 GAAP EPS of -$0.37 beats by $0.06.Cash, cash equivalents and short- and long-term marketable securities was $129.6 million as of September…

Seeking Alpha | November 14, 2022

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal ex

Yahoo | November 14, 2022

Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 12, 2022

Read More 'ELYM' Stories Here

ELYM Price Returns

1-mo 19.94%
3-mo 15.96%
6-mo 26.64%
1-year -54.55%
3-year N/A
5-year N/A
YTD 4.90%
2022 -64.91%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5676 seconds.